Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33182657/
Enormous advances have been made in the understanding and treatment of human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) in the last 30 years that have resulted in...
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
Source : https://link.springer.com/article/10.1007/s12325-020-01552-2
Endocrine therapy (ET) is integral to the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC). Aromatase inhibitors (AIs; e.g., anastrozole, letrozole, exemestane),...
PRIME PubMed | A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers
Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai,...
and MAPK—Crosstalk as Opportunity for Cancer Treatment&ie=UTF-8&oe=UTF-8
Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy
Source : https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02607-2
Background Metastatic breast cancer (mBC) is a complex and life-threatening disease and although it is difficult to cure, patients can benefit from sequential anticancer treatment, including endocrine therapy, targeted therapy...